21% off

British National Formulary (BNF) 83 | March 2022

Name: British National Formulary (BNF) 83 | March 2022
SKU: 9780857114341
Price: 220.00 MYR
Availability: InStock

ISBN: 9780857114341 | Publisher: Pharmaceutical Press | GoodReads

RM220.00

In stock

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

100% Original Free Return

Related Products

The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Extensive content updates in the BNF 83 edition include:

New monographs for:

- Acarizax® [house dust mite extract] for house dust mite allergic rhinitis or house dust mite allergic asthma
- Adakveo® [crizanlizumab] for vaso-occlusive crises in sickle-cell disease
- Adtralza® [tralokinumab] for atopic eczema
- Bijuve® [estradiol with progesterone] for menopausal symptoms
- Evrenzo® [roxadustat] for symptomatic anaemia associated with chronic kidney disease
- Evrysdi® [risdiplam] for 5q spinal muscular atrophy
- Kesimpta® [ofatumumab] for multiple sclerosis
- Klisyri® [tirbanibulin] for actinic keratosis on face or scalp
- Lagevrio® [molnupiravir] for COVID-19
- Leqvio® [inclisiran] for primary hypercholesterolaemia or mixed dyslipidaemia
- Lumykras® [sotorasib] for non-small cell lung cancer with KRAS G12C mutation
- Ontozry® [cenobamate] for focal seizures with or without secondary generalisation
- Orladeyo® [berotralstat] for hereditary angioedema
- Pemazyre® [pemigatinib] for cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
- Ponvory® [ponesimod] for multiple sclerosis
- Rukobia® [fostemsavir] for HIV drug-resistant infection
- Ryaltris® [mometasone furoate with olopatadine] for allergic rhinitis
- Ryeqo® [relugolix with estradiol and norethisterone acetate] for uterine fibroids
- Verquvo® [vericiguat] for chronic heart failure with reduced ejection fraction
- Zibor® [bemiparin sodium] for prophylaxis of deep-vein thrombosis in general and orthopaedic surgery, and prevention of clotting in extracorporeal circuits

MHRA advice on:

Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use
Aflibercept (Eylea®) solution for intravitreal injection: higher risk of intraocular pressure increase with the pre-filled syringe
Atezolizumab (Tecentriq®) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
CDK4/6 inhibitors: reports of interstitial lung disease and pneumonitis, including severe cases
Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years
Dapagliflozin (Forxiga®) 5mg should no longer be used for the treatment of type 1 Diabetes Mellitus
Levothyroxine sodium: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
Oral retinoid medicines: temporary monitoring advice during coronavirus (COVID-19) pandemic
Tofacitinib (Xeljanz®): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors, and new measures to minimise risk
Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
Venetoclax (Venclyxto®): updated recommendations on tumour lysis syndrome (TLS) in chronic lymphocytic leukaemia (CLL) patients
Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist
Other significant changes include updated guidance on:
- COVID-19 updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including reports of myocarditis and pericarditis with the Pfizer/BioNTech and Moderna vaccines
- Advice on use of Dapagliflozin in renal impairment, including new indication for chronic kidney disease
- Diabetic hyperglycaemic emergencies
- Direct-acting oral anticoagulants
- Emergency contraception
- Malaria prophylaxis in-line with Public Health England recommendations
- Management of acne
- Management of acute coronary syndromes
- Management of anaphylaxis
- Management of secondary bacterial infection of common skin conditions
- Management of nausea and vomiting during pregnancy
- Prescribing in renal impairment
- Rabies vaccine and post-exposure management
- Recommended insulin regimens in type 1 diabetes
- Tetanus vaccine and the use of immunoglobulin for tetanus infection and prophylaxis in-line with Public Health England recommendations